Asahi Chemicals and Janssen-Kyowa have launched Pierre Fabre's selectiveserotonin and noradrenaline receptor inhibitor, milnacipran, in Japan for the treatment of depression. The product, which is known as Ixel in France, will be sold as Toledomin in the Japanese market. This is the first product of its class to be commercialized in Japan, said Pierre Fabre, adding that it will enter a market which, until last year and the entrance of the selective serotonin receptor inhibitors, was dominated by the tricyclic class of drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze